Stiff person syndrome

From Wikipedia, the free encyclopedia

This article or section appears to contain a large number of buzzwords and may require cleanup.
Please help rewrite this article to make it more concrete and meaningful, removing tautologies, obvious statements and excessive abstraction. (talk)

**Stiff person syndrome**
*Classification & external resources*
ICD-10	G 25.8
ICD-9	333.91
OMIM	184850
DiseasesDB	12428
eMedicine	neuro/353
MeSH	C10.114.812

Stiff person syndrome (SPS) (or occasionally, stiff-man syndrome) is a rare neurologic disorder of unknown etiology.

1 History
2 Symptoms and prognosis
3 Postulated Causes
4 Treatment
5 References
6 See also
7 External links

[edit] History

SPS was first described by Moersch and Woltman at the Mayo Clinic in 1956 ^[1].

[edit] Symptoms and prognosis

Those with the illness experience progressive, fluctuating tonic muscle contractions, particularly the axial musculature. Depression and anxiety are often noted although this may be a result of discomfort due to stiffness, rather than underlying neurochemical abnormalities. MRI detection of GABA in the brain have demonstrated reduced levels in stiff-person syndrome ^[2].

Prognosis is variable and there is no reliable predictor of speed and severity of disease onset. Muscle tetany may led to muscle rupture and broken bones, or problems swallowing and breathing in severe cases [3].

[edit] Postulated Causes

Because many patients with SPS have circulating antibodies to the enzyme glutamic acid decarboxylase (GAD), an autoimmune cause of the disease has been postulated. However, GAD antibodies cannot be the sole cause, as most Type I diabetics possess anti-GAD antibodies, yet the frequency of SPS among Type I diabetics is 1 in 10000^[4]. The GAD protein regions (epitopes) recognized by these antibodies may differ in each disease^[5].

[edit] Treatment

Treatment is mostly palliative with muscle relaxants which enhance GABA production such as benzodiazepines, which lose their effectiveness as the illness progresses. In the absence of double-blind, placebo-controlled class A trials to determine treatment efficacy, some authorities recommend humane trials of immunosuppressive therapy, plasmapheresis or intravenous immunoglobulin infusion.

[edit] References

↑ MOERSCH FP, WOLTMAN HW (1956). "Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases". Mayo Clin Proc 31 (15): 421-7. PMID 13350379.
Murinson BB (2004). "Stiff-person syndrome". Neurologist 10 (3): 131-7. PMID 15140273.
↑ Hampe C, Hammerle L, Bekris L, Ortqvist E, Kockum I, Rolandsson O, Landin-Olsson M, Törn C, Persson B, Lernmark A (2000). "Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes". J Clin Endocrinol Metab 85 (12): 4671-9. PMID 11134126.
↑ Levy L, Dalakas M, Floeter M (1999). "The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid". Ann Intern Med 131 (7): 522-30. PMID 10507962.